Heart failure kills more people globally than any other ailments, yet there is no ultimate treatment for the condition.
Our goal is to develop and commercialize an effective and reasonably-priced therapy for heart failure using a specific fibroblast cells we call “VCF”, that we obtain from the patient’s own heart.
Our approach to heart failure therapy is quite different from other technologies in a sense that we do not want to replace what is “broken”, but rather we want to repair the damage by enhancing the cells’ own ability to heal.
Metcela’s core patented technology involves a particular population of cardiac fibroblasts, namely VCAM-1-positive cardiac fibroblast (VCF)*. VCAM-1-positive cardiac fibroblasts are known to replenish and re-establish the damaged cardiac muscles and the microenvironment surrounding them.
By using the patients’ own cells, we are aiming to provide an effective and efficient alternative therapies to patients of heart failure.
*Patent granted in Japan (No.6241893) in 2017, and is currently pending in the U.S. and Europe